Henlius Reports Positive ASTRIDE U.S. Bridging Study Results
Henlius said the ASTRIDE U.S. bridging study of serplulimab plus chemotherapy for first-line extensive-stage small cell lung cancer showed favorable median overall survival.
Related stories
Universal Music Group Reports Third-Quarter and Nine-Month Results
M impact | EQUITY | Oct 29, 2026, 04:54 PM UTC
Eutelsat to Gain Access to More Than Twice Current OneWeb Capacity
The added capacity is expected to support estimated service revenue of more than €10 billion over 2032–2040.
M impact | EQUITY | Oct 29, 2026, 04:46 PM UTC
Median Technologies Reports Q3 iCRO Revenue of €6.7M, Backlog of €90.9M
Q3 2026 iCRO revenue rose 14.4% year over year. The company reported a record order backlog of €90.9M and cash of €58.3M at September 30, 2026. Year-to-date revenue was €18.5M, ver
M impact | EQUITY | Oct 29, 2026, 04:45 PM UTC
Nasdaq Falls 1.20% as Dow and S&P 500 Also Decline
The Nasdaq fell 1.20%, while the Dow dropped 0.35% and the S&P 500 fell 0.32%.
M impact | EQUITY | Oct 29, 2026, 04:45 PM UTC
Eutelsat Reports First-Quarter 2026-27 Revenue Growth
LEO revenues increased, driving growth in Connectivity revenues.
M impact | EQUITY | Oct 29, 2026, 04:45 PM UTC
S&P 500 falls 26.87 points, or 0.35%
M impact | EQUITY | Oct 29, 2026, 04:45 PM UTC